2021
Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control [version 2; peer review: 2 approved].
Bléry M, Mrabet-Kraiem M, Morel A, Lhospice F, Bregeon D, Bonnafous C, Gauthier L, Rossi B, Remark R, Cornen S, Anceriz N, Viaud N, Trichard S, Carpentier S, Joulin-Giet A, Grondin G, Liptakova V, Kim Y, Daniel L, Haffner A, Macagno N, Pouyet L, Perrot I, Paturel C, Morel Y, Steinle A, Romagné F, Narni-Mancinelli E, Vivier E.Open Res Eur. 2021 Oct 27;1:107. doi: 10.12688/openreseurope.13314.2.
Increased Concentrations of Circulating Soluble MHC Class I-Related Chain A (sMICA) and sMICB and Modulation of Plasma Membrane MICA Expression: Potential Mechanisms and Correlation With Natural Killer Cell Activity in Systemic Lupus Erythematosus.
Hervier B, Ribon M, Tarantino N, Mussard J, Breckler M, Vieillard V, Amoura Z, Steinle A, Klein R, Kötter I, Decker P.
Front Immunol. 2021 May 3;12:633658. doi: 10.3389/fimmu.2021.633658. eCollection 2021. PMID: 34012432 Free PMC article.
The NKG2D ligand ULBP4 is not expressed by human monocytes.
Lazarova M, Kim Y, Steinle A.
PLoS One. 2021 Feb 8;16(2):e0246726. doi: 10.1371/journal.pone.0246726.
eCollection 2021. PMID: 33556116 Free PMC article.